Aquestive Therapeutics, Inc. is a pharmaceutical company developing medicines to deliver complex molecules through non-invasive administration methods. The company operates two primary technology platforms: PharmFilm, a proprietary oral film drug delivery technology, and AdrenaVerse, an epinephrine prodrug platform. Its pipeline includes Anaphylm (dibutepinephrine) sublingual film for the treatment of severe allergic reactions and anaphylaxis, as well as AQST-108 topical gel. Aquestive manufactures four licensed commercialized products, including Libervant, Sympazan, and Exservan, which are marketed by licensees in the U.S. and globally. The company also provides contract manufacturing and packaging services for oral films, creams, and lotions to pharmaceutical partners. Founded in 2005, Aquestive serves patients and healthcare providers across multiple regions, focusing on improving treatment adherence and reducing the burden of invasive therapies.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage aquestive.com
Sector Healthcare IR page investors.aquestive.com
Tags
oral film technology, epinephrine prodrug, anaphylaxis treatment, drug delivery, contract manufacturing, sublingual film, buccal film, alopecia areata, central nervous system, pharmaceutical development, PharmFilm, AdrenaVerse, Anaphylm, AQST-108, Libervant, Sympazan, Exservan, Zuplenz, Suboxone
Press page —

Metrics

Valuation  
Market cap $ 444.62M
Market cap (USD) $ 444.62M
P/E -5.53
PEG —
P/BV -6.28
P/S 9.10
P/OCF -11.18
P/FCF -10.93
Dividend yield —
Turnover / mcap —
Returns  
ROE 248.9%
ROI -392.8%
ROIC -249.8%
Profit margin -188.1%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score -70.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 44.545M 57.561M 50.583M 47.68M 50.832M 45.849M 52.609M 67.43M 66.918M
Net profit -83.784M -44.137M -7.87M -54.41M -70.539M -55.783M -66.246M -61.376M -8.943M
Free cash flow -52.994M -35.918M -7.375M -10.813M -33.892M -45.976M -60.873M -14.815M 3.756M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 6.46 3.56 2.02 0.9 3.89 5.35 5.82 6.3 —
Price performance 12m 0.81 0.76 1.24 -0.77 -0.27 -0.08 -0.08 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 6.18M — — — — — 8.47M 7.34M 17.8M
↳ YoY growth -13.3% +141.9%
Borrowings, current (USD) — — — — — — — — — 9.99M
Borrowings, non-current (USD) — — — — — — 33.4M 27.5M 32.5M 27.5M
Lease liabilities (USD) — — — 0.00 3.57M 2.85M 5.34M 5.96M 5.62M 5.08M
Cash and deposits (USD) 9.21M 17.4M 60.6M 49.3M 31.8M 28M 27.3M 23.9M 71.5M 121M
Intangible assets (USD) — 254,000 204,000 153,000 102,000 51,000 1.44M 1.28M 0.00 0.00
Right-of-use assets (USD) — — — 0.00 3.45M 2.73M 5.21M 5.56M 5.18M 4.62M
Net debt (borrowings + leases - cash) (USD) — — — — — — 11.5M 9.6M -33.4M -88.6M
Cash flow detail
Operating cash flow (USD) — 5.82M -13M -60.2M -45.5M -33M -9.79M -6.38M -35.8M -52.4M
Purchases of property, plant and equipment (USD) — -2.07M -1.82M -663,000 -517,000 -913,000 -1.02M -995,000 -159,000 -562,000
Purchases of intangible assets (USD) — — — — — 0.00 -1.5M 0.00 — —
Change in inventories (cash effect) (USD) — -1.13M -1.43M 2.58M 398,000 -1.58M -1.74M -989,000 725,000 -126,000
Change in payables (cash effect) (USD) — 2.94M 11.3M -7.87M -5.19M 1.23M 1.63M -1.02M 2.78M 19.5M
Interest paid (cash effect) (USD) — -5.81M -6.05M -7.34M -8.49M -6.44M -6.44M -4.6M -7.1M -6.1M
Income taxes paid (cash effect) (USD) — — — — — — — 0.00 -305,000 0.00
Share-based compensation (USD) — 0.00 29.9M 7.07M 6.58M 6.82M 4.38M 2.69M 7.1M 7.62M
Free cash flow (OCF - PPE - intangibles) (USD) — 3.76M -14.8M -60.9M -46M -33.9M -12.3M -7.38M -35.9M -53M
Income detail
Research and development expense (USD) — 22.1M 23.1M 20.6M 19.9M 17M 17.5M 13.1M 20.3M 17.2M
↳ 5y CAGR -4.6% -10.7% -0.3% -2.9%
Total comprehensive income (USD) — -11.4M -61.4M -66.2M -55.8M -70.5M -54.4M -7.87M -44.1M -83.8M
Comprehensive income to owners (USD) — -11.4M -61.4M -66.2M -55.8M -70.5M -54.4M -7.87M -44.1M -83.8M
Provision for credit losses (USD) — 0.00 53,000 66,000 198,000 0.00 0.00 26,000 -14,000 0.00
Credit cost ratio (credit losses / average receivables) (%) — — — — — — — — 0.2% 0.0%
Reported Sep 4, 2018 Mar 14, 2019 Mar 14, 2019 May 5, 2020 Mar 9, 2021 Mar 31, 2023 Mar 5, 2024 Mar 5, 2025 Mar 5, 2025 Aug 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Regulation FD Disclosure.

Aquestive Therapeutics, Inc. (the "Company") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. A copy of the Company's investor presentation given to investors, analysts and others at the Jefferies Global Healthcare Conference on November 16, 2026 is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The investor presentation is available on the Company’s website located at www.aquestive.com, although the Company reserves the right to discontinue that availability at any time.

Regulation FD Disclosure.

Aquestive Therapeutics, Inc. (the "Company") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. A copy of the Company’s investor presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The investor presentation is available on the Events and Presentations Page of the Investors section of the Company’s website located at www.aquestive.com, although the Company reserves the right to discontinue that availability at any time.

11.05.26 at 7:00 AM EST

PDF Version

WARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, today announced that multiple oral and poster presentations will be featured at the 2026 American College of Allergy, Asthma, and Immunology (ACAAI) Annual Meeting, taking place November 12-16, 2026, in Phoenix, Arizona. The presentations will highlight research evaluating the pharmacokinetic and pharmacodynamic profile of its investigational product candidate Anaphylm™ (dibutepinephrine) sublingual film and healthcare provider perspectives on epinephrine delivery for the treatment of anaphylaxis.

An oral presentation, titled “Dibutepinephrine Pharmacokinetics/Pharmacodynamics in Patients With and Without Symptoms of a Type I Allergic Reaction,” is scheduled to be presented during Distinguished Industry and Late-breaking Oral Abstracts – Session 1 on Saturday, November 14, 2026, at 4:43 pm MST, by Jay A. Lieberman, MD.

An oral presentation, titled “Pharmacokinetics and Pharmacodynamics of Top-of-Tongue Placement of Dibutepinephrine Sublingual Film” is scheduled to be presented during Distinguished Industry and Late-breaking Oral Abstracts – Session 1 on Saturday, November 14, 2026, at 5:23 pm MST, by Matthew Greenhawt, MD, MBA, MSc.

Poster presentation details are as follows:

**Poster Title:**Healthcare Provider Perspectives on Unmet Needs and Clinical Considerations for Epinephrine Delivery in Anaphylaxis Lead Author: Karen Rance, DNP, CPNP Presentation Time: Friday, Nov. 13 at 3:05 pm MST

**Poster Title:**Pharmacodynamic Effects of Sublingual Epinephrine Film AQST-109 at Low Systemic Epinephrine Exposures Lead Author: David B.K. Golden, MD Presentation Time: Friday, Nov. 13, at 3:20 pm MST

The abstracts will be available online at annualmeeting.acaai.org on November 12, 2026.

About Anaphylm™ (dibutepinephrine) Sublingual Film

Anaphylm™ (dibutepinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a phone or wallet, and is designed to withstand weather excursions such as exposure to rain and/or sunlight. If approved by the United States Food and Drug Administration (FDA), Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis. The Anaphylm trade name for AQST-109 has been conditionally approved by the FDA. Final approval of the Anaphylm proprietary name is conditioned on FDA approval of the product candidate.

About Aquestive Therapeutics

Aquestive is a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates with its headquarters in New Jersey and U.S.-based manufacturing facilities in Indiana. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm®. Aquestive's AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis, and AQST-108 (epinephrine) topical gel for various potential dermatological conditions. For more information, visit Aquestive.com and follow us on LinkedIn.

Forward-Looking Statement

Certain statements in this press release include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "may," "will," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of Anaphylm™ (dibutepinephrine) sublingual film for the proposed indication of severe allergic reactions, including anaphylaxis through the U.S. Food and Drug Administration regulatory review and approval process; the potential benefits Anaphylm could bring to patients, and other statements that are not historical facts.

These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including delays to the timing, costs and success of its product development activities, clinical trials and regulatory applications, including relating to Anaphylm (dibutepinephrine) sublingual film, and other uncertainties affecting the Company described in the "Risk Factors" section and elsewhere in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company undertakes no obligation to update any forward-looking statement after the date of this press release, whether as a result of new information, future events or otherwise, except as required by applicable law.

PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.

Investor Contact: Brian Korb astr partners [email protected]

Subscribe to our Email Alerts

Receive the latest posters, presentations, and data with our clinical trial portal.

Prompts

Aquestive Therapeutics, Inc. (ticker AQST), listed in United States.

ETFs Holding Aquestive Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
SURI 1.51% 278,723 $ 1.031M Nov 17, 2026
FSCC 0.30% 211,973 $ 1.083M Aug 31, 2026
MSSM 0.01% 11,637 $ 59.465K Aug 31, 2026